Instituto Valenciano Oncologia; Oncologia Medica

Valencia 46009

0 studies enrolling now · 8 studies all time

What they study most

Advanced BRAFV600 Wild-type Melanoma, Basal Cell Carcinoma, Carcinoma, Transitional Cell, Colorectal Cancer, Neoplasms, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer

Studies at this site

• A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer — Stopped early
• A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) — Completed
• A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection — Stopped early
• A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma — Stopped early
• A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) — Completed
• An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol — Completed
• A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer — Completed
• A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas — Completed